ArticleBMC nephrology2026
The neutrophil-to-lymphocyte ratio as a predictive marker for acute kidney injury in hospitalized sepsis patients: a prospective cohort study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis-associated acute kidney injury (SA-AKI) is a frequent and severe complication of sepsis that substantially increases morbidity and mortality. The neutrophil-to-lymphocyte ratio (NLR), obtained from routine complete blood counts, has emerged as a potential early inflammatory marker; however, its predictive value for SA-AKI remains insufficiently characterized, particularly in real-world hospital settings in Southeast Asia. This study aimed to evaluate the predictive performance of admission NLR for SA-AKI in hospitalized patients with sepsis.
methodsIn this prospective, single-center cohort study, 112 adult patients meeting Sepsis-3 criteria were consecutively enrolled at a tertiary hospital in Thailand between July 2024 and February 2025. Admission NLR was derived from the first routine complete blood count obtained within 24 h of admission. The primary outcome was the development of AKI within 7 days, defined by Kidney Disease: Improving Global Outcomes (KDIGO) creatinine criteria. Receiver operating characteristic (ROC) analysis evaluated the predictive performance of NLR alone and in combination with routinely available clinical variables. Multivariable logistic regression was performed to adjust for clinically relevant covariates.
resultsThe mean age of the cohort was 77 ± 11 years, and 32 patients (28.6%) developed AKI. Admission NLR was significantly higher in patients who developed AKI than in those who did not (median 20.2 [IQR 11.9-47.3] vs. 9.1 [IQR 5.1-14.3]; P < 0.001). An NLR cut-off of ≥ 12.8 predicted AKI with an area under the curve (AUC) of 0.78 (95% CI 0.69-0.88), sensitivity of 75.0%, and specificity of 72.5%. In multivariable analysis, NLR (adjusted odds ratio [aOR] 5.01, 95% CI 1.75-14.35; P = 0.003) and serum albumin (aOR 0.19, 95% CI 0.06-0.58; P = 0.004) were independently associated with AKI. Combining NLR with serum albumin improved model discrimination, yielding an AUC of 0.83 (95% CI 0.73-0.93). Patients with AKI had a significantly longer hospital stay than those without AKI (median 11 [IQR 6-14] vs. 7 [IQR 4-10.5] days; P = 0.039).
conclusionsAdmission NLR is independently associated with the development of SA-AKI and demonstrates moderate predictive performance for early risk stratification. Integration of NLR with serum albumin further improves model discrimination. These findings support the potential role of routinely available inflammatory and nutritional indices for SA-AKI risk stratification; however, external validation of the NLR cut-off in independent multicenter cohorts is warranted before routine clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.